65 related articles for article (PubMed ID: 22731929)
1. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Quan FM; Perez M; Johnson E
Cancer Biother Radiopharm; 2012 Sep; 27(7):442-5. PubMed ID: 22731929
[TBL] [Abstract][Full Text] [Related]
2. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
[TBL] [Abstract][Full Text] [Related]
3. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Quan W; Knupp C; Quan F; Walker P
Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
[TBL] [Abstract][Full Text] [Related]
4. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
[TBL] [Abstract][Full Text] [Related]
5. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
6. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Quan WD; Quan FM; King LA; Walker PR
Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
[TBL] [Abstract][Full Text] [Related]
7. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
[TBL] [Abstract][Full Text] [Related]
8. High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Apr; 24(2):181-3. PubMed ID: 19409039
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
[TBL] [Abstract][Full Text] [Related]
10. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
11. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
[TBL] [Abstract][Full Text] [Related]
13. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
[TBL] [Abstract][Full Text] [Related]
14. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Quan WD; Gagnon GA; Walker PR; Quan FM
Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
[TBL] [Abstract][Full Text] [Related]
15. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma.
Quan W; Brick W; Vinogradov M; Taylor WC; Khan N; Burgess R
Cancer Biother Radiopharm; 2004 Jun; 19(3):350-4. PubMed ID: 15285881
[TBL] [Abstract][Full Text] [Related]
16. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.
Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Dean G; Moore J; Bradley EC
Bull N Y Acad Med; 1989 Jan; 65(1):128-44. PubMed ID: 2532554
[TBL] [Abstract][Full Text] [Related]
17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].
Mitchell MS; Kempf RA; Harel W; Shau H; Boswell WD; Lind S; Bradley EC
J Clin Oncol; 1988 Mar; 6(3):409-24. PubMed ID: 2965219
[TBL] [Abstract][Full Text] [Related]
20. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
